CaMKs are Ca
2+/calmodulin-dependent protein kinases that translate intracellular calcium increases into signaling cascades regulating neuronal transmission, synaptic plasticity, circuit development, cognition, cell-cycle progression, and cancer-related functions
[1][2][3]. Mechanistically, CaMKII gains autophosphorylation-mediated autonomy, whereas CaMKI and CaMKIV depend on CaMKK-dependent phosphoswitch activation, creating distinct pathway logic among related isoforms
[1]. In ischemic stroke models, CaMKII mediates neuronal cell death, neuroinflammation, and endothelial barrier dysfunction, while CaMKK/CaMKIV signaling supports blood-brain barrier integrity and transcriptional activation of neuroprotective molecules
[4][5]. In cardiac models, CaMKIIδ predominates in the heart, where nuclear δB regulates hypertrophic gene expression and cytoplasmic δC affects excitation-contraction coupling and apoptosis
[6]. Compared with related isoforms, CaMKI regulates G
1, whereas CaMKII regulates G
2/M and the metaphase-anaphase transition, supporting isoform-specific experimental design in proliferative disease research
[2]. For experimental applications, KN-93 and KN-62 inhibited RANKL-induced osteoclastogenesis, ERK phosphorylation, CREB activity, cathepsin K expression, and bone resorption
[7]. Structural CAMKK1 studies identified exploitable differences between CAMKK1 and CAMKK2, supporting design of specific inhibitors
[8].